Sijbrands et al. evaluated the response to simvastatin (20 mg per day) in 27 FH patients, for nine weeks and found a similar percentage of LDL-C reduction in patients with confirmed LDLR and APOB mutations when compared to those with no mutation found [31]. This evidence concerns the gene LDLR and familial hyperaldosteronism.